Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Translational Therapeutics

Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer

British Journal of Cancer (2024)Cite this article

Subjects

We want to thank Dr. Rafael Rosell for his comments about our study. We agree with his comment on the well-known roles of YAP1’s Ser397 phosphorylation [1]. It is known that, under physiological conditions, Ser397 phosphorylation creates a phosphodegron motif that targets YAP1 for cytoplasmic retention and degradation, as we discussed extensively in our publication [2]:

“While YAP1 phosphorylation at Ser397 is frequently associated with its targeting for cytoplasmic retention and proteasomal degradation in a Hippo-dependent manner [25,26,27], its role in the context of cancer remains ambiguous […]”

“While YAP1 phosphorylation at Ser397 is frequently associated with its targeting for cytoplasmic retention and proteasomal degradation in a Hippo-dependent manner [25,26,27], its role in the context of cancer remains ambiguous […]”

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rosell R. RE: Reply to Rio-Vilariño and colleagues’ article and misconception about YAP1 Ser 397 phosphorylation function. Br J Cancer. 2024;130:1892.

  2. Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, del Puerto-Nevado L, et al. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. Br J Cancer. 2024;130:1402–13.

  3. Chang SS, Yamaguchi H, Xia W, Lim SO, Khotskaya Y, Wu Y, et al. Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene. 2017;36:1265–75.

    Article  CAS  PubMed  Google Scholar 

  4. Lv M, Gong Y, Liu X, Wang Y, Wu Q, Chen J, et al. CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties. Sig Transduct Target Ther. 2023;8:1–19.

    Article  Google Scholar 

  5. Brown GR, Hem V, Katz KS, Ovetsky M, Wallin C, Ermolaeva O, et al. Gene: a gene-centered information resource at NCBI. Nucleic Acids Res. 2015;43:D36–42.

    Article  CAS  PubMed  Google Scholar 

  6. Gu Y, Chen Y, Wei L, Wu S, Shen K, Liu C, et al. ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation. Nat Commun. 2021;12:6711.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bora-Singhal N, Nguyen J, Schaal C, Perumal D, Singh S, Coppola D, et al. YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem Cells. 2015;33:1705–18.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the grant PI19/01231 funded by AEI and the European Union. A.R-V contract was funded by the programme “CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD (PFIS)”, grant FI20/00213 from the Instituto de Salud Carlos III (ISC-III) and co-funded by the European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”) associated with the project PI19/01231.

Author information

Authors and Affiliations

  1. Translational Oncology Division, Oncohealth Institute, IIS—Fundación Jiménez Díaz University Hospital (IIS-FJD, UAM), Madrid, Spain

    Anxo Río-Vilariño, Jesús García-Foncillas & Arancha Cebrián

Authors
  1. Anxo Río-Vilariño
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesús García-Foncillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arancha Cebrián
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Writing—original draft: ARV, AC; writing—review and editing: ARV, AC, JGF.

Corresponding authors

Correspondence to Jesús García-Foncillas or Arancha Cebrián.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Río-Vilariño, A., García-Foncillas, J. & Cebrián, A. Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer. Br J Cancer (2024). https://doi.org/10.1038/s41416-024-02771-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41416-024-02771-y

Search

Advanced search

Quick links